Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: A randomized controlled trial

Pediatric Research

Volumn 62, Issue 6, 2007, Pages 725-730

  Hafkamp, Anja M ^a   Nelisse Haak, Rineke ^b   Sinaasappel, Maarten ^b   Oude Elferink, Ronald P J ^c   Verkade, Henkjan J ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FECES LIPID; PHENOBARBITAL; PLACEBO; TETRAHYDROLIPSTATIN;

ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRIGLER NAJJAR SYNDROME; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG RESPONSE; FAT INTAKE; FEMALE; FLATULENCE; GILBERT DISEASE; HUMAN; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; STOMACH CRAMP; STOMACH DISEASE;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; BILIRUBIN; CHILD; COMBINED MODALITY THERAPY; CRIGLER-NAJJAR SYNDROME; CROSS-OVER STUDIES; DIETARY FATS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EATING; FECES; FEMALE; HUMANS; LACTONES; LIPID METABOLISM; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHENOBARBITAL; PHOTOTHERAPY; TREATMENT OUTCOME;

EID: 36348964801     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181598cc5     Document Type: Article

References (26)

1. Crigler JF, Najjar VA 1952 Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 10:169-180
2. Shapiro SM 2005 Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol 25:54-59
3. Van der Veere CN, Jansen PL, Sinaasappel M, Van der Meer R, Van der Sijs H, Rammeloo JA, Goyens P, Van Nieuwkerk CM, Oude Elferink RP 1997 Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology 112:455-462
4. Van der Veere CN, Sinaasappel M, McDonagh AF, Rosenthal P, Labrune P, Odievre M, Fevery J, Otte JB, McClean P, Burk G, Masakowski V, Sperl W, Mowat AP, Vergani GM, Heller K, Wilson JP, Shepherd R, Jansen PL 1996 Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 24:311-315
5. Catz C, Yaffe SJ 1968 Barbiturate enhancement of bilirubin conjugation and excretion in young and adult animals. Pediatr Res 2:361-370
6. Yaffe SJ, Levy G, Matsuzawa T, Baliah T 1966 Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med 275:1461-1466
7. Ostrow JD 1971 Photocatabolism of labeled bilirubin in the congenitally jaundiced (Gunn) rat. J Clin Invest 50:707-718
8. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH 2006 Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 165:306-319
9. Yohannan MD, Terry HJ, Littlewood JM 1983 Long term phototherapy in Crigler-Najjar syndrome. Arch Dis Child 58:460-462
10. Whitington PF, Emond JC, Heffron T, Thistlethwaite JR 1993 Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. Lancet 342:779-780
11. Toietta G, Mane VP, Norona WS, Finegold MJ, Ng P, McDonagh AF, Beaudet AL, Lee B 2005 Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 102:3930-3935
12. Kotal P, Van Der Veere CN, Sinaasappel M, Elferink RO, Vitek L, Brodanova M, Jansen PL, Fevery J 1997 Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia. Pediatr Res 42:195-200
13. Schmid R, Hammaker L 1963 Metabolism and disposition of C14-bilirubin in congenital nonhemolytic jaundice. J Clin Invest 42:1720-1734
14. Clarenburg R, Kao CC 1973 Shared and separate pathways for biliary excretion of bilirubin and BSP in rats. Am J Physiol 225:192-200
15. Chowdhury JR, Wolkoff AW, Roy Chowdhury >NR, Arias IM. 2001 Hereditary jaundice and disorders of bilirubin metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease. Vol. McGraw-Hill, New York, pp 2161-2208
16. Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ 2005 Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology 41:526-534
17. Hafkamp AM, Havinga R, Ostrow JD, Tiribelli C, Pascolo L, Sinaasappel M, Verkade HJ 2006 Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats. Pediatr Res 59:506-512
18. Nishioka T, Hafkamp AM, Havinga R, van Lierop PP, Velvis H, Verkade HJ 2003 Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr 143:327-334
19. Ballinger A, Peikin SR 2002 Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440:109-117
20. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C 2003 Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 92:666-670
21. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J 2005 Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293:2873-2883
22. Guerciolini R 1997 Mode of action of orlistat. Int J Obes Relat Metab Disord 21:S12-S23
23. Van de Kamer JH 1953 Quantitative determination of the saturated and unsaturated higher fatty acids in fecal fat. Scand J Clin Lab Invest 5:30-36
24. Altman DG 1991 Practical Statistics for Medical Research. Chapman & Hall/CRC, London, pp 455-460
25. Pocock SJ 1983 Clinical Trials: A Practical Approach. Wiley & Sons, New York, pp 123-130
26. Vitek L, Zelenka J, Zadinova M, Malina J 2005 The impact of intestinal microflora on serum bilirubin levels. J Hepatol 42:238-243